I agree with Led that in the here and now this doesn't mean much to us.  What I find interesting though is that yesterday when reading as to why the latest group of AD drugs are failing, one potential reason that stuck out to me was that perhaps just taking aim at amyloid plaques was perhaps the wrong target as perhaps the plaques are a result of some disease process that is yet to be identified.  Given that RVX has a broader range of effects and cools or stimulates various processes rather than shutting them down totally, perhaps this is why the RVX team feels there is potential in AD.  It will be interesting to see what the cognitive function aspect of BetOnMace reveals.  Would love to hear what those who have more knowledge than I in this area, such as Bear or BFW, have to say on this subject.